These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15987055)

  • 1. [LFN's evaluation of Inspra illustrates the need of drug committees!].
    Malmström R; Hjemdahl P
    Lakartidningen; 2005 May 30-Jun 5; 102(22):1751-2. PubMed ID: 15987055
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inspra and the drug benefits board: What is the role of the drug committees?].
    Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183
    [No Abstract]   [Full Text] [Related]  

  • 3. [Explanation on indications and cost-efficiency of Inspra].
    Ohlsson-Onerud A; Pettersson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2087; discussion 290-2. PubMed ID: 16097182
    [No Abstract]   [Full Text] [Related]  

  • 4. [An addition concerning spironolactone and eplerenone (Inspra) in heart failure].
    Swedberg K
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1924. PubMed ID: 16044777
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug committees are not necessary--therapeutic recommendations are issued anyway].
    Jönsson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181
    [No Abstract]   [Full Text] [Related]  

  • 6. Ethics and eplerenone.
    Gupta S; Fugh-Berman AJ; Scialli A
    J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
    Alvarez JS; Vílchez FG
    Rev Esp Cardiol; 2001 Feb; 54(2):175-80. PubMed ID: 11181306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone after myocardial infarction?
    Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inspra improves survival for CHF patients.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Jul; 29(7):56-9. PubMed ID: 15238861
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure".
    Stecker EC; McAnulty JH
    Circulation; 2005 Aug; 112(5):e74. PubMed ID: 16061750
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug committees, choice of drugs and drug information].
    Lundh B
    Lakartidningen; 1988 Nov; 85(44):3641-3. PubMed ID: 3199994
    [No Abstract]   [Full Text] [Related]  

  • 20. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.